VANISH

Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs - The New England Journal of Medicine - 2016

Brief Summary:

In patients with ischemic cardiomyopathy and an implantable cardioverter-defibrillator (ICD) who experience recurrent ventricular tachycardia (VT) while receiving first-line antiarrhythmic therapy, VT ablation resulted in a 10% absolute reduction in death, VT storm, and appropriate ICD shocks when compared to escalation of antiarrhythmic drugs. This difference was driven largely by reductions in VT storm and ICD shocks with no significant difference in mortality.

Reference: http://www.ncbi.nlm.nih.gov/pubmed/27149033